Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection - Scorecard - MDSpire
Advertisement
Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection
Clinical Scorecard: Assessment of Pimodivir's Effectiveness and Safety When Used Alongside Standard Care in High-Risk Adolescents and Adults With Influenza A, Both Hospitalized and Outpatient
At a Glance
Category
Detail
Condition
Influenza A infection
Key Mechanisms
Pimodivir is a nonnucleoside PB2 inhibitor targeting influenza A virus replication
Target Population
Hospitalized adolescents, adults, and older adults; high-risk outpatients with influenza A
Care Setting
Hospital inpatient and outpatient settings
Key Highlights
Pimodivir plus standard of care (mostly oseltamivir) showed no clinical benefit over placebo plus standard of care in hospitalized patients based on Hospital Recovery Scale at day 6.
In high-risk outpatients, pimodivir plus standard of care demonstrated a statistically significant shorter median time to resolution of influenza symptoms compared to placebo plus standard of care.
Both phase 3 studies were randomized, double-blind, placebo-controlled, and conducted internationally across multiple sites.
Guideline-Based Recommendations
Diagnosis
Laboratory confirmation of influenza A infection is required for treatment consideration.
Management
Standard of care typically includes neuraminidase inhibitors such as oseltamivir.
Pimodivir 600 mg twice daily for 5 days can be considered in high-risk outpatients to shorten symptom duration.
Pimodivir addition to standard care is not recommended for hospitalized patients due to lack of demonstrated clinical benefit.
Monitoring & Follow-up
Monitor clinical status using Hospital Recovery Scale in hospitalized patients.
Assess symptom resolution timing in outpatient settings.
Observe for adverse events and tolerability during treatment.
Risks
No additional safety concerns identified with pimodivir plus standard care compared to placebo plus standard care.
Resistance to existing antivirals remains a concern, highlighting need for novel agents.
Patient & Prescribing Data
Adolescents (13–17 years), adults (18–65 years), and older adults (66–85 years) with laboratory-confirmed influenza A infection, including hospitalized patients with hypoxia and high NEWS2 scores and high-risk outpatients with comorbidities or age ≥65.
Pimodivir combined with standard care shortened symptom duration in high-risk outpatients but did not improve recovery outcomes in hospitalized patients.
Clinical Best Practices
Initiate antiviral treatment within 72 hours of symptom onset in outpatients and within 96 hours in hospitalized patients for optimal effect.
Use Hospital Recovery Scale to assess clinical status in hospitalized influenza A patients.
Consider patient risk factors such as age and comorbidities when selecting antiviral therapy.
Continue monitoring for emerging antiviral resistance patterns.
Large Swedish cohort study finds children hospitalized for respiratory syncytial virus at older ages have greater risk of subsequent bacterial pneumonia
Machine learning analysis identifies 11 jurisdictions—including the District of Columbia, Massachusetts, and Hawaii—with the highest vulnerability to influenza-like illness.
A large English cohort study found influenza hospitalization more than doubled the short-term risk of new-onset diabetes, with prediabetes and critical care admission among the strongest predictors.
